Drug Profile
Lopinavir/ritonavir - Abbvie
Alternative Names: ABT-378/r; ABT-378/ritonavir; Aluvia; KaletraLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie; University of Alberta
- Class Amides; Antiretrovirals; Carbamates; Pyrimidinones; Small molecules; Thiazoles
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
- Phase II COVID 2019 infections; Primary biliary cirrhosis
Most Recent Events
- 18 Jan 2022 Vanderbilt University Medical Center in collaboration with AbbVie completes the phase II TREATNOW trial in COVID-2019 infections in USA (PO) (NCT04372628)
- 01 Jun 2020 Phase-II clinical trials in COVID-2019 infections in USA (PO) (NCT04372628)
- 09 Jan 2020 Launched for HIV infections in Australia (PO)